John Donofrio Net Worth

John Donofrio biography

John A. Donofrio Jr. serves as Independent Director of the Company. Mr. Donofrio joined our Board of Directors in July 2016. He is a senior finance executive with 24 years of experience in the pharmaceutical industry across a broad range of areas, including consolidated financial reporting, international accounting and internal controls, financial systems development and implementation, cost accounting, inventory management, supply chain, transfer pricing, budget and forecast planning, integration of mergers and acquisitions and business development. He has served as the Chief Financial Officer and Head of Business Development at TrialCard since March of 2018. TrialCare is a technology-driven pharmaceutical services company providing patient access and support programs to the pharmaceutical and biotechnology industries. Prior to joining TrialCard, Mr. Donofrio was the Chief Financial Officer and Head of North American Business Development for Merz North America, or Merz, since August 2013. Merz is a specialty healthcare company that develops and commercializes innovative treatment solutions in aesthetics, dermatology and neurosciences in the United States and Canada. At Merz, Mr. Donofrio is accountable for financial performance, cost management, business development and strategic business planning and analysis for the finance organization in North America. Prior to joining Merz, Mr. Donofrio served as Vice President, Stiefel Global Finance, U.S. Specialty Business and Puerto Rico for Stiefel, a GlaxoSmithKline plc company from July 2009 to July 2013. In that role, Mr. Donofrio was responsible for the financial strategy, management reporting, and overall control framework for the Global Dermatology Business Unit. He was also the Senior Finance Partner accountable for the U.S. Specialty Business Units of GlaxoSmithKline plc. Mr. Donofrio served as a director of Vyrix from February 2014 to April 2015. Mr. Donofrio holds a degree in Accounting from North Carolina State University.

What is the salary of John Donofrio?

As the Independent Director of Aytu BioPharma Inc, the total compensation of John Donofrio at Aytu BioPharma Inc is $239,850. There are 5 executives at Aytu BioPharma Inc getting paid more, with Joshua Disbrow having the highest compensation of $1,043,700.

How old is John Donofrio?

John Donofrio is 52, he's been the Independent Director of Aytu BioPharma Inc since 2016. There are 5 older and 6 younger executives at Aytu BioPharma Inc. The oldest executive at Aytu BioPharma Inc is Michael Macaluso, 67, who is the Independent Director.

What's John Donofrio's mailing address?

John's mailing address filed with the SEC is C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD, CO, 80112.

Insiders trading at Aytu BioPharma Inc

Over the last 9 years, insiders at Aytu BioPharma Inc have traded over $40,722,795 worth of Aytu BioPharma Inc stock and bought 8,465,326 units worth $11,497,374 . The most active insiders traders include Capital, Llc Armistice Capi..., Carl Dockery a Joshua R. Disbrow. On average, Aytu BioPharma Inc executives and independent directors trade stock every 91 days with the average trade being worth of $2,701,531. The most recent stock trade was executed by Greg Pyszczymuka on 30 June 2024, trading 208 units of AYTU stock currently worth $522.

What does Aytu BioPharma Inc do?

aytu bioscience is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. aytu is initially concentrating on prostate cancer, male premature ejaculation and male infertility and plans to expand into other urological indications for which there are significant medical needs. the company currently markets prostascint®, an fda-approved radioimaging agent indicated to detect prostate specific membrane antigen (psma) in the assessment and staging of prostate cancer. the company’s most advanced therapeutic is zertane™, an oral therapeutic entering phase 3 clinical studies in the united states as an as needed treatment for premature ejaculation (pe). aytu is also conducting clinical trials with the company’s mioxsys™ system as a novel, point-of-care diagnostic system with the potential to become a standard of care in the diagnosis and management of male infertility.

Aytu BioPharma Inc executives and stock owners

Aytu BioPharma Inc executives and other stock owners filed with the SEC include:

• Joshua Disbrow,
  Chairman of the Board, Chief Executive Officer
• Joshua R. Disbrow,
  Chairman & CEO
• Jarrett Disbrow,
  Chief Operating Officer
• David Green,
  Chief Financial Officer, Treasurer, Secretary
• Michael Macaluso,
  Independent Director
• John Donofrio,
  Independent Director
• Carl Dockery,
  Independent Director
• Gary Cantrell,
  Independent Director
• Ketan Mehta,
  Director
• James Carbonara,
  IR Contact Officer
• Steven Boyd,
  Director
• Matthew Phillips,
  Executive Vice President - Commercial Operations
• Russ McMahen,
  Sr. VP of R&D
• Topher Brooke,
  Exec. VP of Rare Disease Devel.
• Nate Massari,
  Exec. VP of Rare Disease Operations
• Greg Pyszczymuka,
  Chief Commercial Officer
• Jarrett T. Disbrow Ph.D.,
  Exec. VP of Corp. Operations
• Beth Hecht,
  Director
• Gerald W. Mc Laughlin,
  Director
• Inc. Cerecor,
  10% owner
• Capital Management, Llc Har...,
  
• Gregory A Gould,
  Chief Financial Officer
• Jonathan H Mc Grael,
  Vice President of Sales
• Pharmaceuticals, Inc. Ampio,
  10% owner
• Mark K Oki,
  Chief Financial Officer
• Greg Pyszczymuka,
  Chief Commercial Officer
• Christopher Brooke,
  Chief Operating Officer
• Abhinav Jain,
  
• Vivian H Liu,
  
• Richard I Eisenstadt,
  Chief Financial Officer